IV Busulfex Patient Counseling Information

Myelosuppression: Advise patients of the possibility of developing low blood cell counts and the need for hematopoietic progenitor cell infusion. Instruct patients to immediately report to their healthcare provider if fever develops (see Precautions).
Seizures: Advise patients of the possibility of seizures and that they will be given medication to prevent them. Patients should be asked to report a history of seizure or head trauma (see Precautions).
Hepatic Veno-Occlusive Disease (HVOD): Advise patients of the risks associated with the use of Busulfan (IV Busulfex) as well as the plan for regular blood monitoring during therapy. Specifically inform patients of the following: The risk of veno-occlusive liver disease (see Precautions).
Embryo-fetal Toxicity: Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider with a known or suspected pregnancy (see Precautions and Use in Pregnancy & Lactation).
Females of Reproductive Potential: Advise females and males of reproductive potential to use effective contraception during and after treatment with Busulfan (IV Busulfex) and for 6 months following cessation of therapy (see Use in Pregnancy & Lactation).
Males of Reproductive Potential: Advise males with female sexual partners of reproductive potential to use effective contraception during treatment with Busulfan (IV Busulfex) and for 3 months following cessation of therapy (see Use in Pregnancy & Lactation).
Lactation: Advise females to discontinue breastfeeding during treatment with Busulfan (IV Busulfex) (see Use in Pregnancy & Lactation).
Infertility: Advise females and males of reproductive potential that Busulfan (IV Busulfex) may cause temporary or permanent infertility (see Use in Pregnancy & Lactation).
Cardiac Tamponade: Advise patients of the risk of cardiac tamponade. Instruct patients to report to their healthcare provider symptoms of abdominal pain and vomiting (see Precautions).
Bronchopulmonary Dysplasia: Advise patients of the possibility of bronchopulmonary dysplasia with pulmonary fibrosis with chronic Busulfan (IV Busulfex) therapy. Instruct patients to report symptoms of shortness of breath and cough to their healthcare provider. These symptoms could occur several months or years after therapy with Busulfan (IV Busulfex) (see Precautions).